Drug Trial Radar · NCT00020709
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Last checked: Nov 19, 2026Latest source record: Feb 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
840
Actual
Start
Jun 2001
Primary completion
Feb 2007
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of tumors. It is not yet known whether combination chemotherapy plus radiation therapy is more effective with or without gefitinib in treating non-small cell lung cancer
Conditions
- Adenocarcinoma of the Lung
- Bronchoalveolar Cell Lung Cancer
- Large Cell Lung Cancer
- Squamous Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatinDrug
Given IV
docetaxelDrug
Given IV
etoposideDrug
Given IV
gefitinibDrug
Given orally
radiation therapyRadiation
Undergo radiation therapy
placeboOther
Given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of registration to date of death due to any cause, assessed up to 10 years
- Progression-free survivalTime frame: From date of registration to date of first observation of progressive disease, death due to any cause, assessed up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Southwest Oncology Group (SWOG) Research Base
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.